{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T06:32:32Z","timestamp":1769063552618,"version":"3.49.0"},"reference-count":48,"publisher":"BMJ","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0537-9","type":"journal-article","created":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T13:05:10Z","timestamp":1551186310000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Combination treatment with hypofractionated radiotherapy plus IL-2\/anti-IL-2 complexes and its theranostic evaluation"],"prefix":"10.1136","volume":"7","author":[{"given":"Hua","family":"Jing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hettich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Gaedicke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elke","family":"Firat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Bartholom\u00e4","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1710-0975","authenticated-orcid":false,"given":"Gabriele","family":"Niedermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,2,26]]},"reference":[{"issue":"3","key":"537_CR1","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/nri3156","volume":"12","author":"O Boyman","year":"2012","unstructured":"Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012;12(3):180\u201390. https:\/\/doi.org\/10.1038\/nri3156 .","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"537_CR2","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.it.2015.10.003","volume":"36","author":"N Arenas-Ramirez","year":"2015","unstructured":"Arenas-Ramirez N, Woytschak J, Boyman O. Interleukin-2: biology. Design and Application Trends in immunology. 2015;36(12):763\u201377. https:\/\/doi.org\/10.1016\/j.it.2015.10.003 .","journal-title":"Design and Application Trends in immunology"},{"issue":"1","key":"537_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.immuni.2013.01.004","volume":"38","author":"W Liao","year":"2013","unstructured":"Liao W, Lin JX, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity. 2013;38(1):13\u201325. https:\/\/doi.org\/10.1016\/j.immuni.2013.01.004 .","journal-title":"Immunity."},{"issue":"12","key":"537_CR4","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","volume":"192","author":"SA Rosenberg","year":"2014","unstructured":"Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014;192(12):5451\u20138. https:\/\/doi.org\/10.4049\/jimmunol.1490019 .","journal-title":"J Immunol"},{"key":"537_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cbpa.2014.09.006","volume":"23","author":"RA Rosalia","year":"2014","unstructured":"Rosalia RA, Arenas-Ramirez N, Bouchaud G, Raeber ME, Boyman O. Use of enhanced interleukin-2 formulations for improved immunotherapy against cancer. Curr Opin Chem Biol. 2014;23:39\u201346. https:\/\/doi.org\/10.1016\/j.cbpa.2014.09.006 .","journal-title":"Curr Opin Chem Biol"},{"issue":"5","key":"537_CR6","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4049\/jimmunol.137.5.1735","volume":"137","author":"M Rosenstein","year":"1986","unstructured":"Rosenstein M, Ettinghausen SE, Rosenberg SA. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol. 1986;137(5):1735\u201342.","journal-title":"J Immunol"},{"issue":"26","key":"537_CR7","doi-asserted-by":"publisher","first-page":"11906","DOI":"10.1073\/pnas.1002569107","volume":"107","author":"C Krieg","year":"2010","unstructured":"Krieg C, Letourneau S, Pantaleo G, Boyman O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci U S A. 2010;107(26):11906\u201311. https:\/\/doi.org\/10.1073\/pnas.1002569107 .","journal-title":"Proc Natl Acad Sci U S A"},{"key":"537_CR8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.addr.2017.05.011","volume":"114","author":"L Milling","year":"2017","unstructured":"Milling L, Zhang Y, Irvine DJ. Delivering safer immunotherapies for cancer. Adv Drug Deliv Rev. 2017;114:79\u2013101. https:\/\/doi.org\/10.1016\/j.addr.2017.05.011 .","journal-title":"Adv Drug Deliv Rev"},{"key":"537_CR9","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.coi.2016.03.006","volume":"40","author":"D Neri","year":"2016","unstructured":"Neri D, Sondel PM. Immunocytokines for cancer treatment: past, present and future. Curr Opin Immunol. 2016;40:96\u2013102. https:\/\/doi.org\/10.1016\/j.coi.2016.03.006 .","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"537_CR10","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1277306","volume":"6","author":"C Klein","year":"2017","unstructured":"Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, et al. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Oncoimmunology. 2017;6(3):e1277306. https:\/\/doi.org\/10.1080\/2162402X.2016.1277306 .","journal-title":"Oncoimmunology."},{"issue":"5","key":"537_CR11","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1073\/pnas.0909384107","volume":"107","author":"S Letourneau","year":"2010","unstructured":"Letourneau S, van Leeuwen EM, Krieg C, Martin C, Pantaleo G, Sprent J, et al. IL-2\/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25. Proc Natl Acad Sci U S A. 2010;107(5):2171\u20136. https:\/\/doi.org\/10.1073\/pnas.0909384107 .","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"537_CR12","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.immuni.2015.04.015","volume":"42","author":"JB Spangler","year":"2015","unstructured":"Spangler JB, Tomala J, Luca VC, Jude KM, Dong S, Ring AM, et al. Antibodies to Interleukin-2 elicit selective T cell subset potentiation through distinct conformational mechanisms. Immunity. 2015;42(5):815\u201325. https:\/\/doi.org\/10.1016\/j.immuni.2015.04.015 .","journal-title":"Immunity."},{"key":"537_CR13","doi-asserted-by":"publisher","unstructured":"Arenas-Ramirez N, Zou C, Popp S, Zingg D, Brannetti B, Wirth E, et al. Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2. Science translational medicine. 2016;8(367):367ra166. doi: https:\/\/doi.org\/10.1126\/scitranslmed.aag3187 .","DOI":"10.1126\/scitranslmed.aag3187"},{"issue":"8","key":"537_CR14","doi-asserted-by":"publisher","first-page":"4904","DOI":"10.4049\/jimmunol.0900284","volume":"183","author":"J Tomala","year":"2009","unstructured":"Tomala J, Chmelova H, Mrkvan T, Rihova B, Kovar M. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy. J Immunol. 2009;183(8):4904\u201312. https:\/\/doi.org\/10.4049\/jimmunol.0900284 .","journal-title":"J Immunol"},{"issue":"5769","key":"537_CR15","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1126\/science.1122927","volume":"311","author":"O Boyman","year":"2006","unstructured":"Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science. 2006;311(5769):1924\u20137. https:\/\/doi.org\/10.1126\/science.1122927 .","journal-title":"Science."},{"issue":"1","key":"537_CR16","doi-asserted-by":"publisher","first-page":"306","DOI":"10.4049\/jimmunol.177.1.306","volume":"177","author":"D Kamimura","year":"2006","unstructured":"Kamimura D, Sawa Y, Sato M, Agung E, Hirano T, Murakami M. IL-2 in vivo activities and antitumor efficacy enhanced by an anti-IL-2 mAb. J Immunol. 2006;177(1):306\u201314.","journal-title":"J Immunol"},{"issue":"1","key":"537_CR17","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1084\/jem.171.1.249","volume":"171","author":"RB Cameron","year":"1990","unstructured":"Cameron RB, Spiess PJ, Rosenberg SA. Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action. J Exp Med. 1990;171(1):249\u201363.","journal-title":"J Exp Med"},{"issue":"4","key":"537_CR18","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/00002371-199211000-00007","volume":"12","author":"JR Lange","year":"1992","unstructured":"Lange JR, Raubitschek AA, Pockaj BA, Spencer WF, Lotze MT, Topalian SL, et al. A pilot study of the combination of interleukin-2-based immunotherapy and radiation therapy. Journal of immunotherapy : official journal of the Society for Biological Therapy. 1992;12(4):265\u201371.","journal-title":"Journal of immunotherapy : official journal of the Society for Biological Therapy"},{"key":"537_CR19","doi-asserted-by":"publisher","unstructured":"Seung SK, Curti BD, Crittenden M, Walker E, Coffey T, Siebert JC, et al. Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses. Science translational medicine. 2012;4(137):137ra74. doi: https:\/\/doi.org\/10.1126\/scitranslmed.3003649 .","DOI":"10.1126\/scitranslmed.3003649"},{"issue":"9","key":"537_CR20","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1001\/jamaoncol.2015.2756","volume":"1","author":"S Demaria","year":"2015","unstructured":"Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in Cancer immunotherapy. JAMA oncology. 2015;1(9):1325\u201332. https:\/\/doi.org\/10.1001\/jamaoncol.2015.2756 .","journal-title":"JAMA oncology"},{"issue":"12","key":"537_CR21","doi-asserted-by":"publisher","first-page":"7516","DOI":"10.4049\/jimmunol.174.12.7516","volume":"174","author":"AA Lugade","year":"2005","unstructured":"Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol. 2005;174(12):7516\u201323.","journal-title":"J Immunol"},{"key":"537_CR22","doi-asserted-by":"publisher","unstructured":"Spiotto M, Fu YX, Weichselbaum RR. The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications. Sci Immunol. 2016;1(3). doi: https:\/\/doi.org\/10.1126\/sciimmunol.aag1266 .","DOI":"10.1126\/sciimmunol.aag1266"},{"issue":"2","key":"537_CR23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","volume":"17","author":"L Galluzzi","year":"2017","unstructured":"Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17(2):97\u2013111. https:\/\/doi.org\/10.1038\/nri.2016.107 .","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"537_CR24","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1158\/1078-0432.CCR-14-2676","volume":"21","author":"CM Zegers","year":"2015","unstructured":"Zegers CM, Rekers NH, Quaden DH, Lieuwes NG, Yaromina A, Germeraad WT, et al. Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects. Clin Cancer Res. 2015;21(5):1151\u201360. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2676 .","journal-title":"Clin Cancer Res"},{"issue":"13","key":"537_CR25","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1158\/0008-5472.CAN-15-2644","volume":"76","author":"ZS Morris","year":"2016","unstructured":"Morris ZS, Guy EI, Francis DM, Gressett MM, Werner LR, Carmichael LL, et al. In situ tumor vaccination by combining local radiation and tumor-specific antibody or Immunocytokine treatments. Cancer Res. 2016;76(13):3929\u201341. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-2644 .","journal-title":"Cancer Res"},{"issue":"4","key":"537_CR26","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1414119","volume":"7","author":"NH Rekers","year":"2018","unstructured":"Rekers NH, Olivo Pimentel V, Yaromina A, Lieuwes NG, Biemans R, Zegers CML, et al. The immunocytokine L19-IL2: an interplay between radiotherapy and long-lasting systemic anti-tumour immune responses. Oncoimmunology. 2018;7(4):e1414119. https:\/\/doi.org\/10.1080\/2162402X.2017.1414119 .","journal-title":"Oncoimmunology."},{"key":"537_CR27","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12967-015-0397-0","volume":"13","author":"MM Heuvel van den","year":"2015","unstructured":"van den Heuvel MM, Verheij M, Boshuizen R, Belderbos J, Dingemans AM, De Ruysscher D, et al. NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy. J Transl Med. 2015;13:32. https:\/\/doi.org\/10.1186\/s12967-015-0397-0 .","journal-title":"J Transl Med"},{"key":"537_CR28","doi-asserted-by":"publisher","unstructured":"Takahashi Y, Yasui T, Minami K, Tamari K, Otani K, Seo Y, et al. Radiation Enhances the Efficacy of Antitumor Immunotherapy with an Immunocomplex of Interleukin-2 and Its Monoclonal Antibody. Anticancer research. 2017;37(12):6799\u20136806. doi: https:\/\/doi.org\/10.21873\/anticanres.12140 .","DOI":"10.21873\/anticanres.12140"},{"issue":"6","key":"537_CR29","doi-asserted-by":"publisher","first-page":"E692","DOI":"10.1073\/pnas.1314189111","volume":"111","author":"S Gaedicke","year":"2014","unstructured":"Gaedicke S, Braun F, Prasad S, Machein M, Firat E, Hettich M, et al. Noninvasive positron emission tomography and fluorescence imaging of CD133+ tumor stem cells. Proc Natl Acad Sci U S A. 2014;111(6):E692\u2013701. https:\/\/doi.org\/10.1073\/pnas.1314189111 .","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"537_CR30","first-page":"2434","volume":"35","author":"TH Corbett","year":"1975","unstructured":"Corbett TH, Griswold DP Jr, Roberts BJ, Peckham JC, Schabel FM Jr. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res. 1975;35(9):2434\u20139.","journal-title":"Cancer Res"},{"issue":"16","key":"537_CR31","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.1158\/0008-5472.CAN-15-3451","volume":"76","author":"M Hettich","year":"2016","unstructured":"Hettich M, Lahoti J, Prasad S, Niedermann G. Checkpoint antibodies but not T cell-recruiting Diabodies effectively synergize with TIL-inducing gamma-irradiation. Cancer Res. 2016;76(16):4673\u201383. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-3451 .","journal-title":"Cancer Res"},{"issue":"10","key":"537_CR32","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.4049\/jimmunol.137.10.3354","volume":"137","author":"SM Zurawski","year":"1986","unstructured":"Zurawski SM, Mosmann TR, Benedik M, Zurawski G. Alterations in the amino-terminal third of mouse interleukin 2: effects on biological activity and immunoreactivity. J Immunol. 1986;137(10):3354\u201360.","journal-title":"J Immunol"},{"issue":"3","key":"537_CR33","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1162\/153535003322556877","volume":"2","author":"AM Loening","year":"2003","unstructured":"Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging. 2003;2(3):131\u20137.","journal-title":"Mol Imaging"},{"issue":"8","key":"537_CR34","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1084\/jem.20070543","volume":"204","author":"D Kamimura","year":"2007","unstructured":"Kamimura D, Bevan MJ. Naive CD8+ T cells differentiate into protective memory-like cells after IL-2 anti IL-2 complex treatment in vivo. J Exp Med. 2007;204(8):1803\u201312. https:\/\/doi.org\/10.1084\/jem.20070543 .","journal-title":"J Exp Med"},{"issue":"10","key":"537_CR35","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.7150\/thno.15253","volume":"6","author":"M Hettich","year":"2016","unstructured":"Hettich M, Braun F, Bartholoma MD, Schirmbeck R, Niedermann G. High-resolution PET imaging with therapeutic antibody-based PD-1\/PD-L1 checkpoint tracers. Theranostics. 2016;6(10):1629\u201340. https:\/\/doi.org\/10.7150\/thno.15253 .","journal-title":"Theranostics."},{"issue":"7395","key":"537_CR36","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nature10975","volume":"484","author":"AM Levin","year":"2012","unstructured":"Levin AM, Bates DL, Ring AM, Krieg C, Lin JT, Su L, et al. Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Nature. 2012;484(7395):529\u201333. https:\/\/doi.org\/10.1038\/nature10975 .","journal-title":"Nature."},{"issue":"1","key":"537_CR37","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1248014","volume":"6","author":"SV Hartimath","year":"2017","unstructured":"Hartimath SV, Draghiciu O, van de Wall S, Manuelli V, Dierckx RA, Nijman HW, et al. Noninvasive monitoring of cancer therapy induced activated T cells using [18F]FB-IL-2 PET imaging. Oncoimmunology. 2017;6(1):e1248014. https:\/\/doi.org\/10.1080\/2162402X.2016.1248014 .","journal-title":"Oncoimmunology."},{"issue":"5","key":"537_CR38","doi-asserted-by":"publisher","first-page":"679","DOI":"10.2967\/jnumed.111.091306","volume":"53","author":"V Gialleonardo Di","year":"2012","unstructured":"Di Gialleonardo V, Signore A, Glaudemans AW, Dierckx RA, De Vries EF. N-(4-18F-fluorobenzoyl)interleukin-2 for PET of human-activated T lymphocytes. J Nucl Med. 2012;53(5):679\u201386. https:\/\/doi.org\/10.2967\/jnumed.111.091306 .","journal-title":"J Nucl Med"},{"key":"537_CR39","doi-asserted-by":"publisher","unstructured":"van Brummelen EMJ, Huisman MC, de Wit-van der Veen LJ, Nayak TK, Stokkel MPM, Mulder ER, et al. (89)Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding. Oncotarget. 2018;9(37):24737\u201324749. doi: https:\/\/doi.org\/10.18632\/oncotarget.25343 .","DOI":"10.18632\/oncotarget.25343"},{"issue":"11","key":"537_CR40","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.1073\/pnas.1416159112","volume":"112","author":"A Tzeng","year":"2015","unstructured":"Tzeng A, Kwan BH, Opel CF, Navaratna T, Wittrup KD. Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution. Proc Natl Acad Sci U S A. 2015;112(11):3320\u20135. https:\/\/doi.org\/10.1073\/pnas.1416159112 .","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"537_CR41","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","volume":"12","author":"EJ Wherry","year":"2011","unstructured":"Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12(6):492\u20139.","journal-title":"Nat Immunol"},{"issue":"1\u20132","key":"537_CR42","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","volume":"65","author":"H Maeda","year":"2000","unstructured":"Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65(1\u20132):271\u201384.","journal-title":"J Control Release"},{"issue":"7620","key":"537_CR43","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nature19330","volume":"537","author":"SJ Im","year":"2016","unstructured":"Im SJ, Hashimoto M, Gerner MY, Lee J, Kissick HT, Burger MC, et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature. 2016;537(7620):417\u201321. https:\/\/doi.org\/10.1038\/nature19330 .","journal-title":"Nature."},{"issue":"3","key":"537_CR44","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.cell.2016.12.022","volume":"168","author":"MH Spitzer","year":"2017","unstructured":"Spitzer MH, Carmi Y, Reticker-Flynn NE, Kwek SS, Madhireddy D, Martins MM, et al. Systemic immunity is required for effective Cancer immunotherapy. Cell. 2017;168(3):487\u2013502 e15. https:\/\/doi.org\/10.1016\/j.cell.2016.12.022 .","journal-title":"Cell."},{"issue":"6","key":"537_CR45","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1084\/jem.20160831","volume":"214","author":"BH Kwan","year":"2017","unstructured":"Kwan BH, Zhu EF, Tzeng A, Sugito HR, Eltahir AA, Ma B, et al. Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses. J Exp Med. 2017;214(6):1679\u201390. https:\/\/doi.org\/10.1084\/jem.20160831 .","journal-title":"J Exp Med"},{"issue":"3","key":"537_CR46","first-page":"507","volume":"56","author":"K Nakagawa","year":"1996","unstructured":"Nakagawa K, Miller FN, Sims DE, Lentsch AB, Miyazaki M, Edwards MJ. Mechanisms of interleukin-2-induced hepatic toxicity. Cancer Res. 1996;56(3):507\u201310.","journal-title":"Cancer Res"},{"issue":"7","key":"537_CR47","doi-asserted-by":"publisher","first-page":"448","DOI":"10.7150\/thno.6592","volume":"3","author":"C Wu","year":"2013","unstructured":"Wu C, Li F, Niu G, Chen X. PET imaging of inflammation biomarkers. Theranostics. 2013;3(7):448\u201366. https:\/\/doi.org\/10.7150\/thno.6592 .","journal-title":"Theranostics."},{"key":"537_CR48","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139\u201348. https:\/\/doi.org\/10.1016\/j.ejca.2015.11.016 .","journal-title":"Eur J Cancer"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0537-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T23:18:55Z","timestamp":1694647135000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0537-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,26]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["537"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0537-9","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,26]]},"assertion":[{"value":"19 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments were performed in accordance with the German Animal License Regulations and were approved by the animal care committee of the Regierungspr\u00e4sidium Freiburg (registration number: G-13\/082).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"55"}}